Ruiqing Chen1,2, Ye Li1,2, Ke Song1,2, Lingbing Li1,2, Chenyu Shen1,2, Pengkai Ma3, Zhijun Wang1,2,4. 1. Department of Interventional Radiology, The First Medical Center, Chinese PLA General Hospital, Beijing, China. 2. Department of Interventional Radiology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China. 3. School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China. 4. Department of Geriatric Medicine & National Clinical Research Centre of Geriatric Disease, The Second Medical Center, Chinese PLA General Hospital, Beijing, China.
Abstract
Background: The efficacy of transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) is limited. There are insufficient data on TACE-lenvatinib sequential therapy for HCC with PVTT. We aimed to assess the efficacy and safety of TACE-lenvatinib sequential therapy for the treatment of HCC and PVTT. Methods: We retrospectively reviewed 12 consecutive patients with HCC and PVTT who underwent TACE-lenvatinib sequential therapy between July 2018 and May 2021. Lenvatinib treatment was started 1 week after TACE at a dose of 8 or 12 mg daily depending on the patient weight. Follow-up examinations were performed at 4 week and then every 8 weeks after the first TACE procedure. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR) and adverse events (AEs) were calculated. Survival curves of PFS and OS were estimated using the Kaplan-Meier method. Results: The median OS and PFS were 16.9 and 6.15 months, respectively. The ORR and DCR were 75% and 91.7%, respectively. The most common lenvatinib-related AE was hypertension (33.3%), and the most common TACE-related AE was elevated liver enzymes (100%). No treatment-related deaths or grade 4 events were observed. Conclusions: TACE-lenvatinib sequential therapy may be safe and well tolerated, and may improve OS and PFS for HCC patients with PVTT. Further randomized controlled trials with larger cohorts are needed to confirm its efficacy and safety. 2022 Journal of Gastrointestinal Oncology. All rights reserved.
Background: The efficacy of transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) is limited. There are insufficient data on TACE-lenvatinib sequential therapy for HCC with PVTT. We aimed to assess the efficacy and safety of TACE-lenvatinib sequential therapy for the treatment of HCC and PVTT. Methods: We retrospectively reviewed 12 consecutive patients with HCC and PVTT who underwent TACE-lenvatinib sequential therapy between July 2018 and May 2021. Lenvatinib treatment was started 1 week after TACE at a dose of 8 or 12 mg daily depending on the patient weight. Follow-up examinations were performed at 4 week and then every 8 weeks after the first TACE procedure. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR) and adverse events (AEs) were calculated. Survival curves of PFS and OS were estimated using the Kaplan-Meier method. Results: The median OS and PFS were 16.9 and 6.15 months, respectively. The ORR and DCR were 75% and 91.7%, respectively. The most common lenvatinib-related AE was hypertension (33.3%), and the most common TACE-related AE was elevated liver enzymes (100%). No treatment-related deaths or grade 4 events were observed. Conclusions: TACE-lenvatinib sequential therapy may be safe and well tolerated, and may improve OS and PFS for HCC patients with PVTT. Further randomized controlled trials with larger cohorts are needed to confirm its efficacy and safety. 2022 Journal of Gastrointestinal Oncology. All rights reserved.
Authors: Jorge A Marrero; Laura M Kulik; Claude B Sirlin; Andrew X Zhu; Richard S Finn; Michael M Abecassis; Lewis R Roberts; Julie K Heimbach Journal: Hepatology Date: 2018-08 Impact factor: 17.425
Authors: L-T Chen; E Martinelli; A-L Cheng; G Pentheroudakis; S Qin; G S Bhattacharyya; M Ikeda; H-Y Lim; G F Ho; S P Choo; Z Ren; H Malhotra; M Ueno; B-Y Ryoo; T C Kiang; D Tai; A Vogel; A Cervantes; S-N Lu; C-J Yen; Y-H Huang; S-C Chen; C Hsu; Y-C Shen; J Tabernero; Y Yen; C-H Hsu; T Yoshino; J-Y Douillard Journal: Ann Oncol Date: 2019-12-20 Impact factor: 32.976
Authors: Scott M Wilhelm; Lila Adnane; Philippa Newell; Augusto Villanueva; Josep M Llovet; Mark Lynch Journal: Mol Cancer Ther Date: 2008-10 Impact factor: 6.261
Authors: Jian Lu; Xiu-Ping Zhang; Bin-Yan Zhong; Wan Yee Lau; David C Madoff; Jon C Davidson; Xiaolong Qi; Shu-Qun Cheng; Gao-Jun Teng Journal: Lancet Gastroenterol Hepatol Date: 2019-09